Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults.

Kuznik, Andreas; Bégo-Le-Bagousse, Gaëlle; Eckert, Laurent; Gadkari, Abhijit; Simpson, Eric; Graham, Christopher N; Miles, LaStella; Mastey, Vera; Mahajan, Puneet; Sullivan, Sean D

Kuznik, Andreas; Bégo-Le-Bagousse, Gaëlle; Eckert, Laurent; Gadkari, Abhijit; Simpson, Eric; Graham, Christopher N; Miles, LaStella; Mastey, Vera; Mahajan, Puneet; Sullivan, Sean D.

Afiliação

Kuznik A; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA. andreas.kuznik@regeneron.com.
Bégo-Le-Bagousse G; Sanofi, Chilly-Mazarin, France.
Eckert L; Sanofi, Chilly-Mazarin, France.
Gadkari A; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Simpson E; Department of Dermatology, Oregon Health and Science University, Portland, OR, USA.
Graham CN; RTI Health Solutions, Research Triangle Park, NC, USA.
Miles L; RTI Health Solutions, Research Triangle Park, NC, USA.
Mastey V; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Mahajan P; Sanofi, Bridgewater, NJ, USA.
Sullivan SD; Schools of Pharmacy and Public Health, University of Washington, Seattle, WA, USA.

Dermatol Ther (Heidelb) ; 7(4): 493-505, 2017 Dec.

Article em En | MEDLINE | ID: mdl-28933010

Palavras-chave

Atopic dermatitis; Cost-effectiveness; Dupilumab; Eczema; Health economics; Quality-adjusted life-years

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Idioma: En Revista: Dermatol Ther (Heidelb) Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Suíça

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google